Current testing strategies for hepatitis C virus infection in blood donors and the way forward

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2948-2954

  Marwaha, Neelam ^a   Sachdev, Suchet ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Blood donors; Hepatitis C virus; Immunoassays; Nucleic acid testing; Screening tests

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; VIRUS RNA;

ARTICLE; BLOOD DONOR; BLOOD EXAMINATION; BLOOD SAFETY; BLOOD TRANSFUSION; CHEMILUMINESCENCE IMMUNOASSAY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUCLEIC ACID AMPLIFICATION; PATHOGEN REDUCTION SYSTEM; QUALITY CONTROL; RAPID TEST; REAL TIME POLYMERASE CHAIN REACTION; RISK; SCREENING TEST; SENSITIVITY AND SPECIFICITY; BLOOD; DEVELOPING COUNTRY; HEPACIVIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; SEROLOGY;

BLOOD DONORS; DEVELOPING COUNTRIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; SEROLOGIC TESTS;

EID: 84896459388     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2948     Document Type: Article

References (57)

1. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA 1943; 121: 1332-1334 [DOI: 10.1001/jama.1943.02840170016005]
2. Morgan HV, Williamson DA. Jaundice following Administration of Human Blood Products. Br Med J 1943; 1: 750-753 [PMID: 20784888 DOI: 10.1136/bmj.1.4302.750]
3. Tobler LH, Busch MP. History of posttransfusion hepatitis. Clin Chem 1997; 43: 1487-1493 [PMID: 9265899]
4. GRADY GF, CHALMERS TC. RISK OF POST-TRANSFUSION VIRAL HEPATITIS. N Engl J Med 1964; 271: 337-342 [PMID: 14171801 DOI: 10.1056/NEJM196408132710702]
5. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 1970; 211: 261-265 [PMID: 5466902 DOI: 10.1001/jama.1970.03170020025005]
6. Domen RE. Paid-versus-volunteer blood donation in the United States: a historical review. Transfus Med Rev 1995; 9: 53-59 [PMID: 7719038 DOI: 10.1016/S0887-7963(05)80030-6]
7. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, Schmidt PJ. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77: 691-699 [PMID: 4628213 DOI: 10.7326/0003-4819-77-5-691]
8. Genêt F, Poiraudeau S, Revel M. [Effectiveness and compliance to a center-based short rehabilitation program with a home-based program for chronic low back pain]. Ann Readapt Med Phys 2002; 45: 265-272 [PMID: 12076853 DOI: 10.1126/science.182.4116.1026]
9. Dienstag JL, Purcell HR, Alter HJ, Feinstone SM, Wong DC, Holland PV. Non-A, non-B post-transfusion hepatitis. Lancet 1977; 1: 560-562 [PMID: 65657 DOI: 10.1016/S0140-6736(77)91996-1]
10. Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Barker LF, Pineda-Tamondong G. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978; 1: 463-466 [PMID: 76018 DOI: 10.1016/S0140-6736(78)90132-0]
11. Bradley DW, McCaustland KA, Cook EH, Schable CA, Ebert JW, Maynard JE. Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 1985; 88: 773-779 [PMID: 2981754]
12. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562 DOI: 10.1126/science.2523562]
13. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
14. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012; 12 Suppl 2: S2 [PMID: 23173556 DOI: 10.1186/1471-2334-12-S2-S2]
15. Sharma RR, Cheema R, Vajpayee M, Rao U, Kumar S, Marwaha N, Agnihotri SK. Prevalence of markers of transfusion transmissible diseases in voluntary and replacement blood donors. Natl Med J India 2004; 17: 19-21 [PMID: 15115227]
16. Thakral B, Marwaha N, Chawla YK, Saluja K, Sharma A, Sharma RR, Minz RW, Agnihotri SK. Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. Indian J Med Res 2006; 124: 431-438 [PMID: 17159264]
17. Makroo RN, Walia RS, Chowdhry M, Bhatia A, Hegde V, Rosamma NL. Seroprevalence of anti-HCV antibodies among blood donors of north India. Indian J Med Res 2013; 138: 125-128 [PMID: 24056566]
18. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc 2002; 52: 398-402 [PMID: 12532573]
19. Nagalo BM, Bisseye C, Sanou M, Kienou K, Nebié YK, Kiba A, Dahourou H, Ouattara S, Nikiema JB, Moret R, Zongo JD, Simpore J. Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa. Trop Med Int Health 2012; 17: 247-253 [PMID: 21988100 DOI: 10.1111/j.1365-3156.2011.02902.x]
20. Dessie A, Abera B, Wale F. Seroprevalence of major blood-borne infections among blood donors of Felege Hiwot referral hospital, Northwest Ethiopia. Ethiop J Health Dev 2007; 21: 68-69 [DOI: 10.4314/ejhd.v21i1.10034]
21. Kobayashi S, Koike T, Yoshiki K, Shirai S. [Problems in determination of T and B cells in SLE]. Nihon Rinsho 1978; 36: 3689-3693 [PMID: 310478 DOI: 10.1002/hep.1840150228]
22. Klein HG, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine. 11th ed. Oxford: Blackwell Publishing Ltd, 2005: 712-713
23. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995; 35: 903-910 [PMID: 8604486 DOI: 10.1046/j.1537-2995.1995.351196110893.x]
24. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: 15-18 [PMID: 7536987 DOI: 10.1111/j.1423-0410.1995.tb02538.x]
25. Couroucé AM, Pillonel J. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996; 335: 1609-1610 [PMID: 8927113]
26. Peterson J, Green G, Iida K, Caldwell B, Kerrison P, Bernich S, Aoyagi K, Lee SR. Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection. Vox Sang 2000; 78: 80-85 [PMID: 10765142 DOI: 10.1046/j.1423-0410.2000.7820080.x]
27. Grant PR, Sims CM, Tedder RS. Antification of HCVRNA levels and detection of core antigen in donations before seroconversion. Transfusion 2002; 42: 1032-1036 [PMID: 12385415 DOI: 10.1046/j.1537-2995.2002.00161.x]
28. Couroucé AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Efficacy of HCVcore antigen detection during the preseroconversion period. Transfusion 2000; 40: 1198-1202 [PMID: 11061855 DOI: 10.1046/j.1537-2995.2000.40101198.x]
29. Gu S, Liu J, Zhang H, Gu B, Lai H, Zhou H, He C, Chen Y. Core antigen tests for hepatitis C virus: a meta-analysis. Mol Biol Rep 2012; 39: 8197-8208 [PMID: 22544611 DOI: 10.1007/s11033-012-1667-z]
30. Xie L, Wu XD, Huang DZ, Chen HL, He LX, Wang J, Han DK. Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum. Chin Med J (Engl) 2007; 120: 294-299 [PMID: 17374280]
31. Busch MP, Kleinman SH. Hepatitis C infection: recent insights relevant to transfusion safety. ISBT Sci Ser 2009; 4: 72-79 [DOI: 10.1111/j.1751-2824.2009.01214.x]
32. Lagardère B. [Future vaccines in parasitology]. Bull Soc Pathol Exot 1991; 84: 926-934 [PMID: 1819438]
33. Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, Gallian P, Levayer T, Morel P, Simon N. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-3883 [PMID: 16081925 DOI: 10.1128/JCM.43.8.3877-3883.2005]
34. Laperche S, Elghouzzi MH, Morel P, Asso-Bonnet M, Le Marrec N, Girault A, Servant-Delmas A, Bouchardeau F, Deschaseaux M, Piquet Y. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005; 45: 1965-1972 [PMID: 16371051 DOI: 10.1111/j.1537-2995.2005.00648.x]
35. Jourbert JJ, Dewar JB, Weinberg J, De Beer M, Parker JS, Steele AD. A cost-effective particle agglutination assay to detect viral antibodies in dried blood spots--a simple solution to HIV and HCV screening. Cent Afr J Med 2003; 49: 127-130 [PMID: 15301465]
36. Daniel HD, Abraham P, Raghuraman S, Vivekanandan P, Subramaniam T, Sridharan G. Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies. J Clin Microbiol 2005; 43: 1977-1978 [PMID: 15815036 DOI: 10.1128/JCM.43.4.1977-1978.2005]
37. Montebugnoli L, Borea G, Miniero R, Sprovieri G. A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood. Clin Chim Acta 1999; 288: 91-96 [PMID: 10529461 DOI: 10.1016/S0009-8981(99)00146-1]
38. Desbois D, Vaghefi P, Savary J, Dussaix E, Roque-Afonso AM. Sensitivity of a rapid immuno-chromatographic test for hepatitis C antibodies detection. J Clin Virol 2008; 41: 129-133 [PMID: 18069058 DOI: 10.1016/j.jcv.2007.11.002]
39. Laperche S. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. Transfusion 2013; 53: 816-826 [PMID: 22804482 DOI: 10.1111/j.1537-2995.2012.03797.x]
40. Levi JE. Current concepts in molecular testing. ISBT Sci Ser 2011; 6: 67-71 [DOI: 10.1111/j.1751-2824.2011.01438.x]
41. Roth WK, Seifried E. The German experience with NAT. Transfus Med 2002; 12: 255-258 [PMID: 12220254 DOI: 10.1046/j.1365-3148.2002.00383.x]
42. Schmidt M, Seifried E. Current concepts in serological testing-TTID. ISBT Sci Ser 2011; 6: 61-66 [DOI: 10.1111/j.1751-2824.2011.01437.x]
43. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Hourfar MK, Michel P, Offergeld R, Pichl L, Schmidt M, Schottstedt V, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin CK, Tsoi WC, O'Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelmann M, Flanagan P, Flesland O, Brojer E, Le{ogonek}towska M, Nascimento F, Zhiburt E, Chua SS, Teo D, Stezinar SL, Vermeulen M, Reddy R, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster G, Jennings C, Notari E, Stramer S, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102: 82-90 [PMID: 21933190 DOI: 10.1111/j.1423-0410.2011.01506.x]
44. Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009; 49: 289-300 [PMID: 19000230 DOI: 10.1111/j.1537-2995.2008.01965.x]
45. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002; 42: 862-868 [PMID: 12375658 DOI: 10.1046/j.1537-2995.2002.00129.x]
46. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-264 [PMID: 15660836 DOI: 10.1111/j.1537-2995.2004.04215.x]
47. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504 [PMID: 20345570 DOI: 10.1111/j.1537-2995.2010.02622.x]
48. Candotti D, Allain JP. Molecular virology in transfusion medicine laboratory. Blood Transfus 2013; 11: 203-216 [PMID: 23356973]
49. World Health Organisation-Blood safety. Key global fact and figures in 2011. Last accessed 26 September 2013. Available from: URL: http://www.who.int/bloodsafety/global_database/en/index.html
50. El Ekiaby M, Laperhe S, Moftah M, Burnouf T, Lelie N. The impact of different HCV blood screening technologies on the reduction of transfusion transmitted HCV infection in Egypt. Vox Sang 2009; 96 Suppl 1: 23-24
51. Makroo RN, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary RK, Marwaha N, Bhatia NK, Ganguly AK. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & amp; hepatitis B & amp; C viruses in Indian blood donors. Indian J Med Res 2008; 127: 140-147 [PMID: 18403791]
52. Chatterjee K, Coshic P, Borgohain M, Premchand RM, Chakroborty S, Sunder S. Individual donor nucleic acid testing for blood safety against HIV-1 and hepatitis B and C viruses in a tertiary care hospital. Natl Med J India 2012; 25: 207-209 [PMID: 23278777]
53. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007; 47: 529-539 [PMID: 17319836 DOI: 10.1111/j.1537-2995.2006.01146.x]
54. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2: 1S-29S [PMID: 19686562 DOI: 10.1111/j.1537-2995.2009.02279.x]
55. Teo D, Lam S. Pathogen inactivation. ISBT Sci Ser 2011; 6: 499-453 [DOI: 10.1111/j.1751-2824.2011.01531.x]
56. Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-19 [PMID: 19995680 DOI: 10.1016/j.biologicals.2009.10.019]
57. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30 [PMID: 20093041 DOI: 10.1016/j.biologicals.2009.10.016]